InBios International

medical diagnostic company

Hybrid

Some members of the team work remotely, while others are co-located in one or more offices.

👥51-200

📍Seattle, Washington, United States

InBios International

About InBios International

InBios is a leading biotechnology company in innovative diagnostics for infectious diseases

What InBios International is building

design, development and manufacture of diagnostic tests for emerging infectious diseases and biothreats

Company culture

dedicated

Our team of scientists and engineers have years of experience in developing and manufacturing in vitro diagnostic tests, with additional expertise in the field of infectious diseases.

leadership

InBios has successfully developed proprietary technologies used to create rapid and ELISA based immunodiagnostic assays for the world’s most devastating infectious diseases.

Funding rounds

Company type

For Profit

InBios International news and updates

InBios Receives FDA EUA for COVID-19 IgG Antibody Rapid Test

InBios International Inc., a leading developer of diagnostic tests for emerging infectious diseases, announced today that it received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its SCoV-2 Detect IgG Rapid Test, a qualitative immunoassay for the detection of IgG antibodies to SARS-CoV-2.

Sep 15, 2021 | Ellensburg Daily Record

Curebase, InBios Announce Results of Virtual Clinical Trial of InBios COVID-19 Rapid Detection Test Using Curebase Platform

Study demonstrates efficacy of InBios diagnostics test, Curebase decentralized trials platform

Jul 14, 2021 | Yahoo Finance

InBios Gets FDA Emergency Use Authorization for Point-of-Care SARS-CoV-2 Antibody Test

The US Food and Drug Administration last week granted Emergency Use Authorization to InBios International for its point-of-care SCoV-2 Detect IgG Rapid Test for antibodies against SARS-CoV-2.

Aug 30, 2021 | 360Dx